Drug Detail:Rimegepant (Rimegepant [ ri-me-je-pant ])
Drug Class: CGRP inhibitors
Usual Adult Dose for Migraine
For Acute Treatment of Migraine: 75 mg orally as needed
Maximum dose: 75 mg in a 24-hour period
Comments:
- The safety of using more than 18 doses in a 30-day period is unknown.
Use: For the acute treatment of migraine with or without aura.
Usual Adult Dose for Migraine Prophylaxis
75 mg orally every other day
Use: For the preventative treatment of episodic migraine.
Renal Dose Adjustments
Mild to Severe Renal Impairment (CrCl 15 mL/min or greater): No adjustment recommended
ESRD (CrCl less than 15 mL/min): Avoid use
Liver Dose Adjustments
Mild to Moderate Hepatic Impairment (Child-Pugh A or B): No adjustment recommended
Severe Hepatic Impairment (Child-Pugh C): Avoid use
Dose Adjustments
Concomitant Use with CYP450 3A4 Inhibitors:
- Strong CYP450 3A4 inhibitors: Avoid concomitant administration
- Moderate CYP450 3A4 inhibitors: Avoid a second dose of rimegepant within 48 hours
Concomitant Use with CYP450 3A4 Inducers:
- Strong or moderate CYP450 3A4 inducers: Avoid concomitant administration as this may lead to loss of efficacy of rimegepant
Concomitant Use with P-gp or BCRP:
- Avoid concomitant administration with P-gp or BCRP inhibitors
Precautions
CONTRAINDICATIONS:
- Hypersensitivity to active substance or any product excipients; delayed serious hypersensitivity has occurred
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- Place on tongue (or under tongue) and allow to disintegrate in saliva and swallow; additional liquid is not necessary
- Do not take more than 1 dose in 24-hours
Preparation techniques:
- Use dry hands when opening the blister pack
- Peel back the foil and gently remove the tablet; do not push tablet through foil
- Place tablet on tongue or under tongue as soon as the blister is opened; do not store tablet outside the blister pack for future use
Patient advice:
- Patients should be instructed to read the US FDA-approved patient labeling (Patient Information).
- Patients should be instructed to contact their healthcare provider if they experience signs or symptoms of an allergic reaction.
- Patients should be instructed to speak with healthcare provider about all other medicines they are taking including over the counter medications and herbal supplements.
- Patients should be advised to speak with their healthcare provider if they become pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed during therapy.
Frequently asked questions
- What are the new drugs for the treatment of migraines?
- How do Ubrelvy, Qulipta and Nurtec compare for migraines?
- How fast and effective is Nurtec ODT for migraines?
